Yun Zhong
Stock Analyst at Wedbush
(3.11)
# 1,042
Out of 5,090 analysts
42
Total ratings
54.05%
Success rate
0.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Reiterates: Outperform | $220 | $205.44 | +7.09% | 3 | Nov 18, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $18 → $20 | $7.49 | +167.02% | 2 | Nov 11, 2025 | |
| KROS Keros Therapeutics | Maintains: Neutral | $15 → $16 | $21.69 | -26.23% | 3 | Nov 6, 2025 | |
| IRD Opus Genetics | Initiates: Outperform | $8 | $2.27 | +252.42% | 1 | Oct 29, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Outperform | $70 → $86 | $89.65 | -4.07% | 3 | Oct 28, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $80 → $18 | $14.90 | +20.81% | 2 | Sep 30, 2025 | |
| PASG Passage Bio | Maintains: Outperform | $3 → $40 | $9.21 | +334.31% | 3 | Aug 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $28 | $6.39 | +338.18% | 1 | Aug 11, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Outperform | $9 → $8 | $4.28 | +86.92% | 2 | Aug 7, 2025 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $8 | $3.25 | +146.15% | 1 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 | $3.32 | +863.86% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $10.42 | +15.16% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $28 | $4.40 | +536.36% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.05 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $9.90 | +61.62% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $160 | $22.26 | +618.78% | 11 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $21.33 | +115.66% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.06 | +385.44% | 1 | May 5, 2021 |
Ascendis Pharma
Nov 18, 2025
Reiterates: Outperform
Price Target: $220
Current: $205.44
Upside: +7.09%
Wave Life Sciences
Nov 11, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $7.49
Upside: +167.02%
Keros Therapeutics
Nov 6, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $21.69
Upside: -26.23%
Opus Genetics
Oct 29, 2025
Initiates: Outperform
Price Target: $8
Current: $2.27
Upside: +252.42%
Protagonist Therapeutics
Oct 28, 2025
Maintains: Outperform
Price Target: $70 → $86
Current: $89.65
Upside: -4.07%
MoonLake Immunotherapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $80 → $18
Current: $14.90
Upside: +20.81%
Passage Bio
Aug 13, 2025
Maintains: Outperform
Price Target: $3 → $40
Current: $9.21
Upside: +334.31%
Sagimet Biosciences
Aug 11, 2025
Initiates: Outperform
Price Target: $28
Current: $6.39
Upside: +338.18%
Voyager Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $4.28
Upside: +86.92%
Camp4 Therapeutics
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $3.25
Upside: +146.15%
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $3.32
Upside: +863.86%
Nov 5, 2024
Initiates: Outperform
Price Target: $12
Current: $10.42
Upside: +15.16%
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $4.40
Upside: +536.36%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $5.05
Upside: -
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $9.90
Upside: +61.62%
Dec 22, 2022
Maintains: Buy
Price Target: $125 → $160
Current: $22.26
Upside: +618.78%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $21.33
Upside: +115.66%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $2.06
Upside: +385.44%